WO2002083945A3 - Diagnosis and treatment of cancer: i - Google Patents

Diagnosis and treatment of cancer: i Download PDF

Info

Publication number
WO2002083945A3
WO2002083945A3 PCT/GB2002/001692 GB0201692W WO02083945A3 WO 2002083945 A3 WO2002083945 A3 WO 2002083945A3 GB 0201692 W GB0201692 W GB 0201692W WO 02083945 A3 WO02083945 A3 WO 02083945A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
scn9a
gated
patient
nucleic acid
Prior art date
Application number
PCT/GB2002/001692
Other languages
French (fr)
Other versions
WO2002083945A2 (en
Inventor
James Kenneth Joseph Diss
Raoul Charles Coombes
Mustafa Bilgin Ali Djamgoz
Scott Paton Fraser
Original Assignee
Imp College Innovations Ltd
James Kenneth Joseph Diss
Raoul Charles Coombes
Mustafa Bilgin Ali Djamgoz
Scott Paton Fraser
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imp College Innovations Ltd, James Kenneth Joseph Diss, Raoul Charles Coombes, Mustafa Bilgin Ali Djamgoz, Scott Paton Fraser filed Critical Imp College Innovations Ltd
Priority to JP2002582281A priority Critical patent/JP4541645B2/en
Priority to CA 2443968 priority patent/CA2443968A1/en
Priority to AT02713072T priority patent/ATE527375T1/en
Priority to AU2002244862A priority patent/AU2002244862B2/en
Priority to US10/474,778 priority patent/US7393657B2/en
Priority to EP20020713072 priority patent/EP1377680B1/en
Publication of WO2002083945A2 publication Critical patent/WO2002083945A2/en
Publication of WO2002083945A3 publication Critical patent/WO2002083945A3/en
Priority to US12/069,808 priority patent/US20090074665A1/en
Priority to US12/795,268 priority patent/US20100273866A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

A method of diagnosing cancer comprising the steps of (i) obtaining a sample containing nucleic acid and/or protein from the patient; and (ii) determining whether the sample contains a level of SCN5A (and optionally also SCN9A) voltage-gated Na+ channel nucleic acid or protein associated with cancer. A method of diagnosing breast cancer comprising the steps of (i) obtaining a sample containing nucleic acid and/or protein from the patient; and (ii) determining whether the sample contains a level of voltage-gated Na+ channel nucleic acid or protein, preferably SCN5A or SCN9A, associated with cancer. A method of treating cancer comprising the step of administering to the patient an agent which selectively prevents the function of SCN5A (and optionally also SCN9A) voltage-gated Na+ channel. A method of treating breast cancer comprising the step of administering to the patient an agent which selectively prevents the function of a voltage-gated Na+ channel, preferably SCN5A or SCN9A. Genetic constructs and molecules useful in such methods. The methods and compositions are particularly suited to breast cancer.
PCT/GB2002/001692 2001-04-12 2002-04-11 Diagnosis and treatment of cancer: i WO2002083945A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2002582281A JP4541645B2 (en) 2001-04-12 2002-04-11 Diagnosis and treatment of type I cancer
CA 2443968 CA2443968A1 (en) 2001-04-12 2002-04-11 Diagnosis and treatment of cancer: i
AT02713072T ATE527375T1 (en) 2001-04-12 2002-04-11 DIAGNOSIS AND TREATMENT OF BREAST CANCER WITH SCN5A
AU2002244862A AU2002244862B2 (en) 2001-04-12 2002-04-11 Diagnosis and treatment of cancer: I
US10/474,778 US7393657B2 (en) 2001-04-12 2002-04-11 Diagnosis and treatment of cancer: I
EP20020713072 EP1377680B1 (en) 2001-04-12 2002-04-11 Diagnosis and treatment of breast cancer based upon scn5a
US12/069,808 US20090074665A1 (en) 2001-04-12 2008-02-13 Diagnosis and treatment of cancer:I
US12/795,268 US20100273866A1 (en) 2001-04-12 2010-06-07 Diagnosis and treatment of cancer: i

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28329501P 2001-04-12 2001-04-12
US60/283,295 2001-04-12

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/474,778 Division US7393657B2 (en) 2001-04-12 2002-04-11 Diagnosis and treatment of cancer: I
US12/069,808 Division US20090074665A1 (en) 2001-04-12 2008-02-13 Diagnosis and treatment of cancer:I

Publications (2)

Publication Number Publication Date
WO2002083945A2 WO2002083945A2 (en) 2002-10-24
WO2002083945A3 true WO2002083945A3 (en) 2003-10-30

Family

ID=23085371

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/001692 WO2002083945A2 (en) 2001-04-12 2002-04-11 Diagnosis and treatment of cancer: i

Country Status (7)

Country Link
US (3) US7393657B2 (en)
EP (2) EP1377680B1 (en)
JP (2) JP4541645B2 (en)
AT (1) ATE527375T1 (en)
AU (3) AU2002244862B2 (en)
CA (1) CA2443968A1 (en)
WO (1) WO2002083945A2 (en)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6300108B1 (en) * 1999-07-21 2001-10-09 The Regents Of The University Of California Controlled electroporation and mass transfer across cell membranes
US6892099B2 (en) 2001-02-08 2005-05-10 Minnesota Medical Physics, Llc Apparatus and method for reducing subcutaneous fat deposits, virtual face lift and body sculpturing by electroporation
US8251986B2 (en) 2000-08-17 2012-08-28 Angiodynamics, Inc. Method of destroying tissue cells by eletroporation
US6697670B2 (en) 2001-08-17 2004-02-24 Minnesota Medical Physics, Llc Apparatus and method for reducing subcutaneous fat deposits by electroporation with improved comfort of patients
US6795728B2 (en) 2001-08-17 2004-09-21 Minnesota Medical Physics, Llc Apparatus and method for reducing subcutaneous fat deposits by electroporation
USRE42016E1 (en) 2001-08-13 2010-12-28 Angiodynamics, Inc. Apparatus and method for the treatment of benign prostatic hyperplasia
US6994706B2 (en) 2001-08-13 2006-02-07 Minnesota Medical Physics, Llc Apparatus and method for treatment of benign prostatic hyperplasia
US7130697B2 (en) * 2002-08-13 2006-10-31 Minnesota Medical Physics Llc Apparatus and method for the treatment of benign prostatic hyperplasia
US9278088B2 (en) 2002-02-19 2016-03-08 Xenon Pharmaceuticals Inc. Methods for identifying analgesic agents
US7659082B2 (en) * 2002-02-19 2010-02-09 Xenon Pharmaceuticals Inc. Methods for identifying analgesic agents
US8298222B2 (en) 2003-12-24 2012-10-30 The Regents Of The University Of California Electroporation to deliver chemotherapeutics and enhance tumor regression
AU2004311842C1 (en) 2003-12-24 2011-01-06 The Regents Of The University Of California Tissue ablation with irreversible electroporation
EP1711517A4 (en) * 2004-01-21 2008-02-13 Univ Utah Res Found MUTANT SODIUM CHANNEL NAv1.7 AND METHODS RELATED THERETO
JP4443278B2 (en) * 2004-03-26 2010-03-31 テルモ株式会社 Catheter with expansion body
US20060264752A1 (en) * 2005-04-27 2006-11-23 The Regents Of The University Of California Electroporation controlled with real time imaging
US20060293731A1 (en) * 2005-06-24 2006-12-28 Boris Rubinsky Methods and systems for treating tumors using electroporation
US20060293725A1 (en) * 2005-06-24 2006-12-28 Boris Rubinsky Methods and systems for treating fatty tissue sites using electroporation
US20060293730A1 (en) 2005-06-24 2006-12-28 Boris Rubinsky Methods and systems for treating restenosis sites using electroporation
US8114070B2 (en) * 2005-06-24 2012-02-14 Angiodynamics, Inc. Methods and systems for treating BPH using electroporation
US20070156135A1 (en) * 2006-01-03 2007-07-05 Boris Rubinsky System and methods for treating atrial fibrillation using electroporation
EP2076313A4 (en) * 2006-10-16 2012-07-25 Univ California Gels with predetermined conductivity used in irreversible electroporation of tissue
US20080132885A1 (en) * 2006-12-01 2008-06-05 Boris Rubinsky Methods for treating tissue sites using electroporation
US20080132884A1 (en) * 2006-12-01 2008-06-05 Boris Rubinsky Systems for treating tissue sites using electroporation
US20090136465A1 (en) 2007-09-28 2009-05-28 Intrexon Corporation Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof
KR20100087330A (en) * 2007-11-19 2010-08-04 제넨테크, 인크. Compositions and methods for inhibiting tumor progression
EP2093567A1 (en) * 2008-02-21 2009-08-26 Pangaea Biotech, S.A. Brca1 mRNA expression levels predict survival in breast cancer patients treated with neoadjuvant chemotherapy
US20090247933A1 (en) * 2008-03-27 2009-10-01 The Regents Of The University Of California; Angiodynamics, Inc. Balloon catheter method for reducing restenosis via irreversible electroporation
US20100004623A1 (en) * 2008-03-27 2010-01-07 Angiodynamics, Inc. Method for Treatment of Complications Associated with Arteriovenous Grafts and Fistulas Using Electroporation
US11272979B2 (en) 2008-04-29 2022-03-15 Virginia Tech Intellectual Properties, Inc. System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies
US10272178B2 (en) 2008-04-29 2019-04-30 Virginia Tech Intellectual Properties Inc. Methods for blood-brain barrier disruption using electrical energy
US9283051B2 (en) 2008-04-29 2016-03-15 Virginia Tech Intellectual Properties, Inc. System and method for estimating a treatment volume for administering electrical-energy based therapies
US9867652B2 (en) 2008-04-29 2018-01-16 Virginia Tech Intellectual Properties, Inc. Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds
US10245098B2 (en) 2008-04-29 2019-04-02 Virginia Tech Intellectual Properties, Inc. Acute blood-brain barrier disruption using electrical energy based therapy
US11254926B2 (en) 2008-04-29 2022-02-22 Virginia Tech Intellectual Properties, Inc. Devices and methods for high frequency electroporation
US10702326B2 (en) 2011-07-15 2020-07-07 Virginia Tech Intellectual Properties, Inc. Device and method for electroporation based treatment of stenosis of a tubular body part
US8992517B2 (en) 2008-04-29 2015-03-31 Virginia Tech Intellectual Properties Inc. Irreversible electroporation to treat aberrant cell masses
US10238447B2 (en) 2008-04-29 2019-03-26 Virginia Tech Intellectual Properties, Inc. System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress
US8926606B2 (en) * 2009-04-09 2015-01-06 Virginia Tech Intellectual Properties, Inc. Integration of very short electric pulses for minimally to noninvasive electroporation
US9198733B2 (en) 2008-04-29 2015-12-01 Virginia Tech Intellectual Properties, Inc. Treatment planning for electroporation-based therapies
CA2722296A1 (en) 2008-04-29 2009-11-05 Virginia Tech Intellectual Properties, Inc. Irreversible electroporation to create tissue scaffolds
US10117707B2 (en) 2008-04-29 2018-11-06 Virginia Tech Intellectual Properties, Inc. System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies
WO2009137800A2 (en) * 2008-05-09 2009-11-12 Angiodynamics, Inc. Electroporation device and method
US9173704B2 (en) * 2008-06-20 2015-11-03 Angiodynamics, Inc. Device and method for the ablation of fibrin sheath formation on a venous catheter
US9681909B2 (en) * 2008-06-23 2017-06-20 Angiodynamics, Inc. Treatment devices and methods
US20100152725A1 (en) * 2008-12-12 2010-06-17 Angiodynamics, Inc. Method and system for tissue treatment utilizing irreversible electroporation and thermal track coagulation
WO2010085765A2 (en) * 2009-01-23 2010-07-29 Moshe Meir H Therapeutic energy delivery device with rotational mechanism
US8231603B2 (en) * 2009-02-10 2012-07-31 Angiodynamics, Inc. Irreversible electroporation and tissue regeneration
US11638603B2 (en) 2009-04-09 2023-05-02 Virginia Tech Intellectual Properties, Inc. Selective modulation of intracellular effects of cells using pulsed electric fields
US11382681B2 (en) 2009-04-09 2022-07-12 Virginia Tech Intellectual Properties, Inc. Device and methods for delivery of high frequency electrical pulses for non-thermal ablation
USD630321S1 (en) 2009-05-08 2011-01-04 Angio Dynamics, Inc. Probe handle
WO2010138919A2 (en) 2009-05-28 2010-12-02 Angiodynamics, Inc. System and method for synchronizing energy delivery to the cardiac rhythm
US9895189B2 (en) 2009-06-19 2018-02-20 Angiodynamics, Inc. Methods of sterilization and treating infection using irreversible electroporation
CA2773983A1 (en) 2009-09-11 2011-03-17 University Of Utah Research Foundation Mutant sodium channel nav1.7 and methods related thereto
US20110118732A1 (en) 2009-11-19 2011-05-19 The Regents Of The University Of California Controlled irreversible electroporation
WO2011163499A2 (en) * 2010-06-23 2011-12-29 Opko Curna, Llc Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
US9700368B2 (en) 2010-10-13 2017-07-11 Angiodynamics, Inc. System and method for electrically ablating tissue of a patient
WO2012088149A2 (en) 2010-12-20 2012-06-28 Virginia Tech Intellectual Properties, Inc. High-frequency electroporation for cancer therapy
PE20140593A1 (en) 2011-03-16 2014-05-10 Amgen Inc POWERFUL AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7
CA2877994C (en) 2011-07-21 2019-09-24 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Targeted osmotic lysis of cancer cells
US9078665B2 (en) 2011-09-28 2015-07-14 Angiodynamics, Inc. Multiple treatment zone ablation probe
ITMO20120015A1 (en) * 2012-01-26 2013-07-27 Guescini Michele Proprieta Al 25 PROCESSING METHOD FOR THE QUANTITATIVE DETERMINATION OF NUCLEIC ACIDS
US9414881B2 (en) 2012-02-08 2016-08-16 Angiodynamics, Inc. System and method for increasing a target zone for electrical ablation
US9888956B2 (en) 2013-01-22 2018-02-13 Angiodynamics, Inc. Integrated pump and generator device and method of use
US10344060B2 (en) 2013-03-12 2019-07-09 Amgen Inc. Potent and selective inhibitors of Nav1.7
AR096927A1 (en) 2013-03-12 2016-02-10 Amgen Inc POWERFUL AND SELECTIVE INHIBITORS OF NaV1.7
US10166321B2 (en) 2014-01-09 2019-01-01 Angiodynamics, Inc. High-flow port and infusion needle systems
EP3143124A4 (en) 2014-05-12 2018-01-17 Virginia Tech Intellectual Properties, Inc. Selective modulation of intracellular effects of cells using pulsed electric fields
WO2016100325A1 (en) 2014-12-15 2016-06-23 Virginia Tech Intellectual Properties, Inc. Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment
US10660691B2 (en) 2015-10-07 2020-05-26 Angiodynamics, Inc. Multiple use subassembly with integrated fluid delivery system for use with single or dual-lumen peristaltic tubing
US10905492B2 (en) 2016-11-17 2021-02-02 Angiodynamics, Inc. Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode
CN111132614A (en) 2017-07-20 2020-05-08 路易斯安娜州立大学监测委员会，农业和机械学院 Targeted osmotic lysis of malignant cancer cells using pulsed magnetic field gradients
US11607537B2 (en) 2017-12-05 2023-03-21 Virginia Tech Intellectual Properties, Inc. Method for treating neurological disorders, including tumors, with electroporation
US11311329B2 (en) 2018-03-13 2022-04-26 Virginia Tech Intellectual Properties, Inc. Treatment planning for immunotherapy based treatments using non-thermal ablation techniques
US11925405B2 (en) 2018-03-13 2024-03-12 Virginia Tech Intellectual Properties, Inc. Treatment planning system for immunotherapy enhancement via non-thermal ablation
US11950835B2 (en) 2019-06-28 2024-04-09 Virginia Tech Intellectual Properties, Inc. Cycled pulsing to mitigate thermal damage for multi-electrode irreversible electroporation therapy
EP4077672A1 (en) 2019-12-20 2022-10-26 F. Hoffmann-La Roche AG Enhanced oligonucleotides for inhibiting scn9a expression

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599673A (en) * 1995-03-09 1997-02-04 University Of Utah Research Foundation Long QT syndrome genes
WO2002018637A2 (en) * 2000-09-02 2002-03-07 Imperial College Innovations Limited Diagnosis and treatment of prostate cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5168053A (en) 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US5149796A (en) 1989-08-31 1992-09-22 City Of Hope Chimeric DNA-RNA catalytic sequences
US5180818A (en) 1990-03-21 1993-01-19 The University Of Colorado Foundation, Inc. Site specific cleavage of single-stranded dna
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5541104A (en) 1991-05-23 1996-07-30 Ludwig Institute For Cancer Research Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1
ATE378406T1 (en) 1992-08-31 2007-11-15 Ludwig Inst Cancer Res ISOLATED NONAPEPTIDE DERIVED FROM THE MAGE-3 GENE AND PRESENTED BY HLA-A1 AND ITS APPLICATIONS
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
ATE209690T1 (en) 1994-03-01 2001-12-15 Ludwig Inst Cancer Res DETERMINATION OF CANCERICAL CONDITIONS BY THE GENE EXPRESSION OF A MEMBER OF THE MELANOMA GROUP, MAGE
AU3374795A (en) 1994-08-29 1996-03-22 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
US5859699A (en) 1997-02-07 1999-01-12 Arcturus Engineering, Inc. Laser capture microdissection analysis vessel
US7399599B2 (en) * 2000-07-10 2008-07-15 Vertex Pharmaceuticals (San Diego) Llc Ion channel assay methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599673A (en) * 1995-03-09 1997-02-04 University Of Utah Research Foundation Long QT syndrome genes
WO2002018637A2 (en) * 2000-09-02 2002-03-07 Imperial College Innovations Limited Diagnosis and treatment of prostate cancer

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DISS J K J ET AL: "Expression of skeletal muscle-type voltage-gated Nachannel in rat and human prostate cancer cell lines", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 427, no. 1, 1 May 1998 (1998-05-01), pages 5 - 10, XP004259019, ISSN: 0014-5793 *
FLETCHER J E ET AL: "Sodium channel in human malignant hyperthermia.", ANESTHESIOLOGY. UNITED STATES MAY 1997, vol. 86, no. 5, May 1997 (1997-05-01), pages 1023 - 1032, XP008013417, ISSN: 0003-3022 *
GRANT A O: "Molecular biology of sodium channels and their role in cardiac arrhythmias.", THE AMERICAN JOURNAL OF MEDICINE. UNITED STATES MAR 2001, vol. 110, no. 4, March 2001 (2001-03-01), pages 296 - 305, XP002238105, ISSN: 0002-9343 *
GRIMES J A ET AL: "Differential expression of voltage-activated Na+ currents in two prostatic tumour cell lines: contribution to invasiveness in vitro.", FEBS LETTERS. NETHERLANDS 7 AUG 1995, vol. 369, no. 2-3, 7 August 1995 (1995-08-07), pages 290 - 294, XP002194656, ISSN: 0014-5793 *
LANLADO M E ET AL: "EXPRESSION AND FUNCTIONAL ANALYSIS OF VOLTAGE-ACTIVATED NA+ CHANNELS IN HUMAN PROSTATE CANCER CELL LINES AND THEIR CONTRIBUTION TO INVASION IN VITRO", AMERICAN JOURNAL OF PATHOLOGY, PHILADELPHIA, PA, US, vol. 4, no. 150, April 1997 (1997-04-01), pages 1213 - 1221, XP008002039, ISSN: 0002-9440 *
SMITH P ET AL: "Sodium channel protein expression enhances the invasiveness of rat and human prostate cancer cells", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 423, no. 1, 13 February 1998 (1998-02-13), pages 19 - 24, XP004261853, ISSN: 0014-5793 *

Also Published As

Publication number Publication date
AU2007254583B2 (en) 2010-12-02
JP2004533239A (en) 2004-11-04
US7393657B2 (en) 2008-07-01
JP4541645B2 (en) 2010-09-08
EP1377680A2 (en) 2004-01-07
AU2002244862B2 (en) 2007-09-20
US20100273866A1 (en) 2010-10-28
AU2007254583A1 (en) 2008-01-24
JP2010063458A (en) 2010-03-25
US20090074665A1 (en) 2009-03-19
WO2002083945A2 (en) 2002-10-24
AU2007254583C1 (en) 2011-07-07
CA2443968A1 (en) 2002-10-24
EP2341148A3 (en) 2012-05-30
US20040146877A1 (en) 2004-07-29
EP2341148A2 (en) 2011-07-06
AU2011200879A1 (en) 2011-03-24
ATE527375T1 (en) 2011-10-15
EP1377680B1 (en) 2011-10-05

Similar Documents

Publication Publication Date Title
WO2002083945A3 (en) Diagnosis and treatment of cancer: i
CY1107715T1 (en) Diagnosis And Treatment Of Prostate Cancer
HK1055446A1 (en) Method for isolation of rna from formalin-fixed paraffin-embedded tissue specimens
MXPA02011656A (en) Nrg 2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods.
WO2004053079A3 (en) Compositions, splice variants and methods relating to ovarian specific genes and proteins
WO2001034802A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001000828A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2003016464A3 (en) Cancer specific oligosaccharide sequences and use thereof
WO2001079286A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2004071273A3 (en) Method of employing elevation of marinobufagenin in determining the presence of preeclampsia and related apparatus
WO2001057207A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2004053075A3 (en) Compositions, splice variants and methods relating to breast specific genes and proteins
WO2005017102A3 (en) Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins
WO2002002623A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2001073031A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2004013311A3 (en) Compositions and methods relating to ovarian specific genes and proteins
WO2004022104A3 (en) Foxp2 and uses thereof
WO2003066877A3 (en) Compositions and methods relating to hepatic specific genes and proteins
WO2004052290A3 (en) Compositions, splice variants and methods relating to breast specific genes and proteins
WO2003020899A3 (en) Compositions and methods relating to lung specific genes and proteins
WO2003038051A3 (en) Method of inducing apoptosis in hyperproliferative cells
WO2001016158A3 (en) Bridging integrator-2 (bin2) nucleic acid molecules and proteins and uses therefor
WO2004053077A3 (en) Compositions,splice variants and methods relating to breast specific genes and proteins
YU5002A (en) Compositions and method for the therapy and diagnosis of lung cancer
WO2001027276A3 (en) Dna sequences from breast tumor and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002244862

Country of ref document: AU

Ref document number: 2443968

Country of ref document: CA

Ref document number: 2002582281

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002713072

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002713072

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10474778

Country of ref document: US